Hence, particular forms of mutant p53 may directly enhance the resistance of tumor cells to anticancer agents and confer a selective survival advantage during chemotherapy.26The relevance of these findings should be extended to cells lines and patients with Burkitt's lymphoma. This evidence concerns the gene TP53 and neoplasm.